Does LEUPROLIDE Cause Injection site discolouration? 27 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Injection site discolouration have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.0% of all adverse event reports for LEUPROLIDE.
27
Reports of Injection site discolouration with LEUPROLIDE
0.0%
of all LEUPROLIDE reports
0
Deaths
3
Hospitalizations
How Dangerous Is Injection site discolouration From LEUPROLIDE?
Of the 27 reports, 3 (11.1%) required hospitalization.
Is Injection site discolouration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 27 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Injection site discolouration?
ETANERCEPT (1,846)
DUPILUMAB (779)
CERTOLIZUMAB PEGOL (597)
ADALIMUMAB (554)
EVOLOCUMAB (476)
GLATIRAMER (270)
EXENATIDE (266)
TERIPARATIDE (249)
ASFOTASE ALFA (243)
ENBREL (231)
Which LEUPROLIDE Alternatives Have Lower Injection site discolouration Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM